Early detection without delay
— or discomfort.

The challenge.

Colorectal cancer is the second leading cause of cancer-related deaths, yet screening rates remain low due to fear, discomfort, and the invasiveness of traditional tests. Many cases go undetected until advanced stages, when outcomes are poorer and costs are higher.

The opportunity.

KIFFIK Lab delivers a non-invasive, point-of-care test for colorectal cancer screening — offering a patient-friendly alternative to colonoscopy, blood draws, and stool-based tests. By accessing ISF biomarkers through the skin, our platform enables earlier insight, faster decision-making, and broader screening access.

Clinical application:

  • Routine screening in primary care and outpatient settings

  • Non-invasive option for screening-hesitant populations

  • Expanded access for underserved and remote communities

Potential biomoarkers:

  • Carcinoembryonic antigen (CEA)

  • Methylated DNA markers (e.g., SEPT9)

  • MMP-9 (Matrix metalloproteinase-9)

  • Interleukin-8 (IL-8)

  • Calprotectin (inflammatory marker)

Colorectal cancer can be prevented — if it's detected early. KIFFIK makes screening simpler, faster, and more human.